Cargando…
Evidence-based treatments for eosinophilic esophagitis: insights for the clinician
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Left untreated, EoE progresses to fibrous remodeling and stricture formation that impairs quality of life. Therefore, EoE requires either rep...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777364/ https://www.ncbi.nlm.nih.gov/pubmed/35069803 http://dx.doi.org/10.1177/17562848211068665 |
_version_ | 1784637054513053696 |
---|---|
author | Feo-Ortega, Sara Lucendo, Alfredo J. |
author_facet | Feo-Ortega, Sara Lucendo, Alfredo J. |
author_sort | Feo-Ortega, Sara |
collection | PubMed |
description | Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Left untreated, EoE progresses to fibrous remodeling and stricture formation that impairs quality of life. Therefore, EoE requires either repeated treatments or maintenance therapy. Current guidelines recommend swallowed topical corticosteroids (STCs), proton-pump inhibitors (PPIs), or dietary intervention as initial options to induce and maintain long-term disease remission. Impractical exclusive elemental diets and suboptimal allergy testing-directed food avoidance paved the way for empirical elimination diets. These are moderately effective and highly reproducible in inducing EoE remission and allow for identification of specific food triggers. Step-up strategies, including two- and four-food rather than six-food elimination diets, should be considered as initial approaches for dietary treatment in patients of all ages, as they reduce the need for endoscopic procedures, shorten diagnostic processing time, and avoid unnecessary restrictions. Formulations of STC originally designed for asthma therapy are suboptimal for EoE treatment, with new effervescent orodispersible tablets and viscose formulations designed to coat the esophageal mucosa providing increased effectiveness at reduced doses. The anti-inflammatory effects of PPI in EoE are independent from gastric acid secretion inhibition; despite evidence from observational research, PPIs are the most commonly prescribed first-line therapy for EoE due to their accessibility, low cost, and safety profile. Double doses of PPI only induce remission in half of EoE patients, irrespective of the drug used or patients’ age. Inflammatory rather than stricturing EoE phenotype and treatment duration up to 12 weeks increase chances of achieving EoE remission. Most responders effectively maintain long-term remission with standard PPI doses. Finally, endoscopic dilation should be considered in patients with reduced esophageal caliber or persistent dysphagia despite histological remission. This article provides a state-of-the-art review and updated discussion of current therapies and newly developed options for EoE. |
format | Online Article Text |
id | pubmed-8777364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87773642022-01-22 Evidence-based treatments for eosinophilic esophagitis: insights for the clinician Feo-Ortega, Sara Lucendo, Alfredo J. Therap Adv Gastroenterol Review Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Left untreated, EoE progresses to fibrous remodeling and stricture formation that impairs quality of life. Therefore, EoE requires either repeated treatments or maintenance therapy. Current guidelines recommend swallowed topical corticosteroids (STCs), proton-pump inhibitors (PPIs), or dietary intervention as initial options to induce and maintain long-term disease remission. Impractical exclusive elemental diets and suboptimal allergy testing-directed food avoidance paved the way for empirical elimination diets. These are moderately effective and highly reproducible in inducing EoE remission and allow for identification of specific food triggers. Step-up strategies, including two- and four-food rather than six-food elimination diets, should be considered as initial approaches for dietary treatment in patients of all ages, as they reduce the need for endoscopic procedures, shorten diagnostic processing time, and avoid unnecessary restrictions. Formulations of STC originally designed for asthma therapy are suboptimal for EoE treatment, with new effervescent orodispersible tablets and viscose formulations designed to coat the esophageal mucosa providing increased effectiveness at reduced doses. The anti-inflammatory effects of PPI in EoE are independent from gastric acid secretion inhibition; despite evidence from observational research, PPIs are the most commonly prescribed first-line therapy for EoE due to their accessibility, low cost, and safety profile. Double doses of PPI only induce remission in half of EoE patients, irrespective of the drug used or patients’ age. Inflammatory rather than stricturing EoE phenotype and treatment duration up to 12 weeks increase chances of achieving EoE remission. Most responders effectively maintain long-term remission with standard PPI doses. Finally, endoscopic dilation should be considered in patients with reduced esophageal caliber or persistent dysphagia despite histological remission. This article provides a state-of-the-art review and updated discussion of current therapies and newly developed options for EoE. SAGE Publications 2022-01-19 /pmc/articles/PMC8777364/ /pubmed/35069803 http://dx.doi.org/10.1177/17562848211068665 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Feo-Ortega, Sara Lucendo, Alfredo J. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician |
title | Evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
title_full | Evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
title_fullStr | Evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
title_full_unstemmed | Evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
title_short | Evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
title_sort | evidence-based treatments for eosinophilic esophagitis: insights for
the clinician |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777364/ https://www.ncbi.nlm.nih.gov/pubmed/35069803 http://dx.doi.org/10.1177/17562848211068665 |
work_keys_str_mv | AT feoortegasara evidencebasedtreatmentsforeosinophilicesophagitisinsightsfortheclinician AT lucendoalfredoj evidencebasedtreatmentsforeosinophilicesophagitisinsightsfortheclinician |